Dr. Tom Leemhuis


Dr. Leemhuis received both his undergraduate and graduate degrees from Indiana University.  He is an Associate Professor of Pediatrics at the University of Cincinnati and the Laboratory Director for Hoxworth’s Cell Therapy Laboratory, providing cell processing services for the 3 stem cell transplant programs in Cincinnati and for Akron Children’s Hospital.  His staff performs a variety of stem cell graft manipulation and cryopreservation procedures, as well as participating in the manufacture of cell therapy products for phase 1 and phase 2 clinical trials; including the virus-specific T cells he will be discussing today.   Tom has been with University of Cincinnati in this position since 2001.   


Ph.D., Experimental Hematology, 1993, Indiana University School of Medicine.

Master of Science, Immunology, 1985, Purdue University.

Bachelor of Science, Microbiology, 1978, Indiana University.

Grant and Contracts

  • Service contracts for conducting cell processing support functions for routine “standard of care” hematopoietic stem cell transplants at Jewish Hospital, Kenwood, Ohio, Cincinnati Children’s Hospital, Cincinnati, Ohio, University of Cincinnati Medical Center, and Akron Children’s Hospital, Akron, Ohio.
  • Service contracts for conducting cell processing support functions for the following phase I/II clinical trials:

Donor-Derived Anti-viral Cytotoxic T-cells (CTLs) for Treatment of CMV, EBV and Adenovirus after Allogeneic Stem Cell Transplant .

Third Party Anti-viral Cytotoxic T-cells (CTLs) for Treatment of Viral Infections in Immunocompromised Patients .

A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine.

A Phase 1 Non-Randomized/Phase 2 Randomized Study of ProTmune™ (ex vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Hematologic Malignancies.

  • Heimlich Foundation Grant: “Cellular Immunotherapy for viral diseases post transplant”. 2010 – 2013. $300,000